An engineered bacteria-chitosan hybrid robot for lactate depletion and synergistic STING activation to potentiate bladder cancer immunotherapy
Authors:
- Baodan ZhangBZBaodan Zhang
- Jie ZhuJZJie Zhu
- Zhenyu HongZHZhenyu Hong
- Yuhang WangYWYuhang Wang
- Yunong WangYWYunong Wang
- Fangdie YeFYFangdie Ye
- Liping TaoLTLiping Tao
- Yongyong LuYLYongyong Lu
Open Access
- 25 August 2026
- journal article
- Published by Elsevier in Materials Today Bio
- Vol. 40
Abstract
No abstract availableThis publication has 40 references indexed in Scilit:
- Beyond tumour suppression: cGAS‐STING pathway in urologic malignancies: Context‐dependent duality and therapeutic implicationsClinical and Translational Medicine, 2025
- Bimetallic nanoreactor mediates cascade amplification of oxidative stress for complementary chemodynamic-immunotherapy of tumorBiomaterials, 2024
- Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder CancerCurrent Urology Reports, 2024
- Interference of ATP‐Adenosine Axis by Engineered Biohybrid for Amplifying Immunogenic Cell Death‐Mediated Antitumor ImmunotherapyAdvanced Materials, 2024
- Bladder CancerJAMA, 2020
- Recurrent bladder cancer in aging societies: Importance of major histocompatibility complex class I antigen presentationInternational Journal of Cancer, 2020
- Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint TherapyCell Reports, 2019
- PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical TrialsClinical Genitourinary Cancer, 2019
- Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancerCancer Medicine, 2017
- Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell ResponsesCell, 2015